Norris Medicines Ltd

Fri 4/09/2026,15:27:0 | BSE : NORRIS

₹13.65-0.64 (-4.48%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 14.50

Previous Close

₹ 14.29

Volume

520

Mkt Cap ( ₹ Cr)

₹ 13.65

High

₹ 14.85

Low

₹ 13.63

52 Week High

₹ 19.63

52 Week Low

₹ 12.00

Book Value Per Share

₹ -15.47

Dividend Yield

₹ 0.00

Face Value

₹₹10.00

What's Your Call?

Collective community sentiment on Norris Medicines Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Norris Medicines Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Norris Medicines - Reg. 34 (1) Annual Report.

    4 Sep 2026, 7:57PM Annual Report of the Company for the Financial year 2025-26.
  • Norris Medicines - Notice Of 35Th Annual General Meeting Of The Company For The Financial Year 2025-26

    4 Sep 2026, 7:49PM Notice of 35th Annual General Meeting of the Company for the Financial Year 2025-26
  • Norris Medicines - Intimation Of Book Closure For 35Th AGM Of The Company.

    4 Sep 2026, 7:43PM Intimation of Book Closure for 35th AGM of the Company
  • Norris Medicines - Board Meeting Outcome for Of Board Meeting Held On Thurday, 03Rd September, 2026 Pursuant To Regulation 30

    3 Sep 2026, 6:33PM Outcome of the Board Meeting on Thursday, 03rd September, 2026 pursuant to Regulation 30 of the SEBI(LODR) Regulations, 2015
  • Norris Medicines - Announcement under Regulation 30 (LODR)-Change in Management

    14 Aug 2026, 5:35PM Appointment of Mr. Vimal Dhirendra Shah (DIN: 01506655) as a Managing Director (Promoter and Executive) of the Company for a term of 3 (Three) consecu
  • Norris Medicines - Financial Results For The Quarter Ended June 30, 2026

    14 Aug 2026, 5:26PM Financial Results for the Quarter ended June 30,2026
  • Norris Medicines - Board Meeting Outcome for Outcome Of Board Meeting Held On August 14, 2026, Pursuant To Regulation 30 And

    14 Aug 2026, 5:19PM Board Meeting held on August 14, 2026 for the quarter ended June 30, 2026.
  • Norris Medicines - Board Meeting Intimation for Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements, 2

    8 Aug 2026, 2:56PM Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and
  • Norris Medicines - Announcement under Regulation 30 (LODR)-Change in Management

    30 Jul 2026, 6:26PM Intimation relating to appointment of Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) & Key Managerial Personnel (KMP) of the Company in the
  • Norris Medicines - Board Meeting Outcome for Outcome Of The Board Meeting Dated 30Th July, 2026.

    30 Jul 2026, 6:18PM Outcome of Board Meeting held on Thursday, July 30, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regul
  • Norris Medicines has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    21 Jul 2026, 12:40PM As of June 2026, 34.01% is owned by Indian Promoters and 65.99% by Public. <p align=justify> Top five Promoters holding highest number of shares of No
  • Norris Medicines - Certificate Under Reg. 74 (5) Of SEBI (DP) Regulations, 2018

    3 Jul 2026, 3:07PM Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 30 June, 2026.

Key fundamentals

Evaluate the intrinsic value of Norris Medicines Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 6.3872 6.7129 4.9617 5.9819 7.4071
Liabilities 6.3872 6.7129 4.9617 5.9819 7.4071
Equity 9.9258 9.9257 9.9257 9.9257 9.9257
Gross Profit 0.6648 -0.2628 -0.1849 0.9223 -0.0718
Net Profit -0.2806 -1.2374 -1.1867 -1.7494 -3.2634
Cash From Operating Activities 0.5776 0.51 0.1697 1.1995 -1.0094
NPM(%) -3.45 -21.26 -21.05 -20.93 -34.57
Revenue 8.132 5.8201 5.6356 8.3581 9.4384
Expenses 7.4672 6.0829 5.8205 7.4358 9.5102
ROE(%) 1.81 7.99 7.67 11.3 21.09

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Norris Medicines Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 863.00 -0.52 21.76 7.79 -26.19 0.58
Lotus Eye Hospital and Institute Ltd 109.90 -0.68 1563.29 28.39 0.39 0.00
Bharat Immunological and Biologicals Corporation Ltd 15.42 0.72 0.00 58.94 -39.50 0.00
Astec Lifesciences Ltd 552.30 -3.93 0.00 30.42 -363.14 0.00

Company Info

Norris Medicines Limited was established as a private limited company in the state of Maharashtra on 7th September 1990. The company commenced commercial operations in November 1991 with the commissioning of the formulations unit. The unit was set up at a total capacity outlay of Rs 135.85 lakhs, which was financed by equity contribution from the promoters and associates to the extent of Rs 108.12 lakhs and term loan of Rs 27.73 lakhs from Gujarat State Finance Corporation. Norris was converted into a public limited company with effect from 7th March 1992. 1990 Launch of Norris 1992 Launch of Ethical Division and conversion of company into Public Limited company 1994 WHO cGMP Certificate 1995 Major Expansions 1996 Started exporting to European, Middle East, Far East and African Countries 2000 The Company has decided to issue 1,80,00,000 No. of equity shares of Rs. 10 each on preferential/private placement basis at a price not less than Rs. 10 per share to PHC Holdings Ltd., 90,00,000 shares and Positive Healthcare (Asia) Ltd. 2006 -Launching of Diabetic & Cardiac products 2007 - Launching of Dental product range 2012 -Launching of New Molecule Tolperisone with Paracetamol tablet 2013 -Extension in Anti malarial range with Artemether Lumefantrine tablet & dry syrup

Norris Medicines Limited was established as a private limited company in the state of Maharashtra on 7th September 1990. The company commenced commercial operations in November 1991 with the commissioning of the formulations unit. The unit was set up at a total capacity outlay of Rs 135.85 lakhs, which was financed by equity contribution from the promoters and associates to the extent of Rs 108.12 lakhs and term loan of Rs 27.73 lakhs from Gujarat State Finance Corporation. Norris was converted into a public limited company with effect from 7th March 1992. 1990 Launch of Norris 1992 Launch of Ethical Division and conversion of company into Public Limited company 1994 WHO cGMP Certificate 1995 Major Expansions 1996 Started exporting to European, Middle East, Far East and African Countries 2000 The Company has decided to issue 1,80,00,000 No. of equity shares of Rs. 10 each on preferential/private placement basis at a price not less than Rs. 10 per share to PHC Holdings Ltd., 90,00,000 shares and Positive Healthcare (Asia) Ltd. 2006 -Launching of Diabetic & Cardiac products 2007 - Launching of Dental product range 2012 -Launching of New Molecule Tolperisone with Paracetamol tablet 2013 -Extension in Anti malarial range with Artemether Lumefantrine tablet & dry syrup

Parent Organisation

Norris Medicines Ltd.

Founded

07/09/1990

Managing Director

NSE Symbol

FAQ